Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TP-MCT (Whole Protein Enteral Nutrition Suspension with Medium Chain Triglycerides) is a nutritionally complete, protein-enriched enteral formula designed for patients with a functioning or partially functioning gastrointestinal tract who require nutritional support. The formulation contains whole proteins (typically derived from casein and soy), carbohydrates (maltodextrin), and a lipid blend that includes a significant proportion of medium-chain triglycerides (MCT). MCTs are utilized to facilitate easier digestion and absorption compared to long-chain fats, making the product particularly suitable for patients with fat malabsorption, high metabolic demands, or those recovering from major surgery. In China, this product is registered as a pharmaceutical enteral nutrition suspension and is commonly used in the perioperative management of patients with primary liver cancer undergoing hepatectomy to improve postoperative recovery and gastrointestinal function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on whole protein enteral nutrition suspension (TP-MCT).